Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs)
Robert Roskoski
Pharmacological Research (2021) Vol. 165, pp. 105422-105422
Closed Access | Times Cited: 75

Showing 1-25 of 75 citing articles:

Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update
Robert Roskoski
Pharmacological Research (2021) Vol. 165, pp. 105463-105463
Closed Access | Times Cited: 306
Properties of FDA-approved small molecule protein kinase inhibitors: A 2023 update
Robert Roskoski
Pharmacological Research (2022) Vol. 187, pp. 106552-106552
Open Access | Times Cited: 242
Properties of FDA-approved small molecule protein kinase inhibitors: A 2022 update
Robert Roskoski
Pharmacological Research (2021) Vol. 175, pp. 106037-106037
Closed Access | Times Cited: 190
Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update
Robert Roskoski
Pharmacological Research (2024) Vol. 200, pp. 107059-107059
Open Access | Times Cited: 170
Curcumin Supplementation and Human Disease: A Scoping Review of Clinical Trials
Timothy Panknin, Carol Howe, Meg Hauer, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 5, pp. 4476-4476
Open Access | Times Cited: 49
Rule of five violations among the FDA-approved small molecule protein kinase inhibitors
Robert Roskoski
Pharmacological Research (2023) Vol. 191, pp. 106774-106774
Open Access | Times Cited: 49
Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis
Robert Roskoski
Pharmacological Research (2023) Vol. 189, pp. 106642-106642
Open Access | Times Cited: 48
Targeting Breast Cancer: An Overlook on Current Strategies
Domenico Iacopetta, Jessica Ceramella, Noemi Baldino, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 4, pp. 3643-3643
Open Access | Times Cited: 48
Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders
Robert Roskoski
Pharmacological Research (2022) Vol. 183, pp. 106362-106362
Closed Access | Times Cited: 63
Development of covalent inhibitors: Principle, design, and application in cancer
Lang Zheng, Yang Li, Defa Wu, et al.
MedComm – Oncology (2023) Vol. 2, Iss. 4
Open Access | Times Cited: 25
Properties of FDA-approved small molecule phosphatidylinositol 3-kinase inhibitors prescribed for the treatment of malignancies
Robert Roskoski
Pharmacological Research (2021) Vol. 168, pp. 105579-105579
Closed Access | Times Cited: 49
Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signaling
Birgit Wilding, Dirk Scharn, Dietrich Böse, et al.
Nature Cancer (2022) Vol. 3, Iss. 7, pp. 821-836
Closed Access | Times Cited: 33
How many kinases are druggable? A review of our current understanding
Brian Anderson, Peter Rosston, Han Wee Ong, et al.
Biochemical Journal (2023) Vol. 480, Iss. 16, pp. 1331-1363
Open Access | Times Cited: 21
Strategy toward Kinase-Selective Drug Discovery
Mingzhen Zhang, Yonglan Liu, Hyunbum Jang, et al.
Journal of Chemical Theory and Computation (2023) Vol. 19, Iss. 5, pp. 1615-1628
Open Access | Times Cited: 17
Insight into Janus kinases specificity: From molecular architecture to cancer therapeutics
Tian‐Hua Wei, Meng‐Yi Lu, Sihui Yao, et al.
MedComm – Oncology (2024) Vol. 3, Iss. 1
Open Access | Times Cited: 7
An Antiherpesviral Host-Directed Strategy Based on CDK7 Covalently Binding Drugs: Target-Selective, Picomolar-Dose, Cross-Virus Reactivity
DongHoon Yu, Sabrina Wagner, Martin Schütz, et al.
Pharmaceutics (2024) Vol. 16, Iss. 2, pp. 158-158
Open Access | Times Cited: 6
Targeted and cytotoxic inhibitors used in the treatment of breast cancer
Robert Roskoski
Pharmacological Research (2024), pp. 107534-107534
Open Access | Times Cited: 6
Targeting Phosphatases and Kinases: How to Checkmate Cancer
Alice Turdo, Caterina D’Accardo, Antonino Glaviano, et al.
Frontiers in Cell and Developmental Biology (2021) Vol. 9
Open Access | Times Cited: 38
Development of the First Covalent Monopolar Spindle Kinase 1 (MPS1/TTK) Inhibitor
Ricardo A. M. Serafim, André da Silva Santiago, Martin P. Schwalm, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 4, pp. 3173-3192
Closed Access | Times Cited: 24
Inhibiting androgen receptor splice variants with cysteine-selective irreversible covalent inhibitors to treat prostate cancer
Thirumagal Thiyagarajan, Suriyan Ponnusamy, Dong‐Jin Hwang, et al.
Proceedings of the National Academy of Sciences (2022) Vol. 120, Iss. 1
Open Access | Times Cited: 24
Targeting tumor endothelial hyperglycolysis enhances immunotherapy through remodeling tumor microenvironment
Yunlong Shan, Qi Ni, Qixiang Zhang, et al.
Acta Pharmaceutica Sinica B (2022) Vol. 12, Iss. 4, pp. 1825-1839
Open Access | Times Cited: 23
Small molecule protein kinase inhibitors approved by regulatory agencies outside of the United States
Robert Roskoski
Pharmacological Research (2023) Vol. 194, pp. 106847-106847
Open Access | Times Cited: 15
Advances in Cancer Therapy: A Comprehensive Review of CDK and EGFR Inhibitors
Mohammed Hawash
Cells (2024) Vol. 13, Iss. 19, pp. 1656-1656
Open Access | Times Cited: 5
Blockade of mutant RAS oncogenic signaling with a special emphasis on KRAS
Robert Roskoski
Pharmacological Research (2021) Vol. 172, pp. 105806-105806
Closed Access | Times Cited: 29
Covalent inhibitors: An ambitious approach for the discovery of newer oncotherapeutics
Rameshwar S. Cheke, Prashant S. Kharkar
Drug Development Research (2023) Vol. 85, Iss. 1
Open Access | Times Cited: 12
Page 1 - Next Page

Scroll to top